What are the drugs for biological immunity therapy in the advanced stage of lung cancer?
The main targets of biological immune therapy drugs for advanced lung cancer were PD - 1/L1, CTLA - 4, etc. Among them, the PD-L1 monoclonal-type drugs included "K drug" pabolizumab,"O drug" nivaliumab, cimepreliumab, sindiliumab, carrelliumab, triplliumab, etc.; The PD-L1 monoclonal-type drugs mainly included atiliumab, duvalliumab, etc. These drugs could be used for biological immunity therapy in the advanced stage of lung cancer. Read more exciting novels for free
What kind of medicine is there to take for lung cancer immunity therapy?
The immune drugs for lung cancer included: PD1 (programmed death receptor 1) inhibition drugs, such as pabolizumb, tirilibizumb, sindilibizumb, and carillibizumb; PD-L1 (programmed cell death-ligand1) inhibition drugs, such as atilibizumb and nivaliumab. In addition, under normal circumstances, you can also use rituxed injection, bevacizumi injection, olapali tablets and other immune therapy drugs. The specific use and efficacy of the medicine needed to be determined according to the individual situation. It was recommended to use it under the guidance of a professional doctor. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of drugs in the advanced stage of preoperative cancer.
There were several types of commonly used drugs for late-stage chemotherapy of intestinal cancer: 1. **5 -fluorouracil-based drugs **: It can achieve anti-tumor effects by suppressing the synthesis of cancer cells 'DNA. It is the most classic chemotherapy drug for Coloreceptor Cancer. 2. ** Oxaliplatin-type drugs **: It is one of the commonly used drugs in chemotherapy for patients with intestinal cancer. It can be combined with other drugs to form a variety of chemotherapy plans. 3. ** Irinotecan-like drugs **: It is also a commonly used drug for chemotherapy of intestinal cancer. It can be used in combination with other drugs. 4. ** Capecitobin (Xeloda)**: After oral administration, the patient's intestine will rapidly absorb it and transform it into an intermediate product in the liver. 5. ** TA- 102 (Trifluridine-Tipirubin Tablets)**: A combination of two compounds, FTD (Trifluridine) and TPi (Tipirubin Hyclate). It is suitable for patients with advanced Colorectalcancer who have been treated with flurouridines, oxaliplatins, and irinotecan but have not achieved good results, as well as patients with metastasized Colorectalcancer who have received targeted treatments such as anti-Vessel-Endothellar Growth factor (Ang-1) and anti-Epidermal Growth Factor-receptor (Ang-1) but have not achieved the expected results. There were many combinations of these drugs, such as two-week application combination and three-week application combination. Different administration methods included oral combination and infusion combination. Different methods could bring different chemotherapy effects to patients with intestinal cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What is the survival rate of targeted drugs in the treatment of advanced lung cancer?
There was a large individual difference in the survival rate of patients with advanced lung cancer after taking targeted drugs. The time from the start of treatment to disease progression or death was 9.2 - 18.9 months, and the general overall survival period was 21.6 - 36 months. Some studies had shown that the average survival time for late-stage lung cancer patients with targeted drugs was about three years, but there were also cases where it was as short as one or two years and as long as ten years. According to the data, after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the medium survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the medium survival time was 6 months. In addition, in some studies, the 1-year, 2-year, 3-year, 4-year, and 5-year overall survival rates of the control group (first-line therapy with a combination of a combination The patient's physical condition, the effect of the targeted therapy, whether the attitude was positive, the degree of cooperation with the treatment, whether the patient had underlying diseases, and the support, care, and financial investment of the family would all affect the survival rate. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the names of the drugs used to treat advanced small cell lung cancer?
The drugs used to treat late-stage small cell lung cancer included TaiShengQi (atilibizab), temoziromide, eloposide, irinotecan, platinum, and topographic. Among them, TaiShengQi (atilibizab) was an immune targeting drug; temozuorm could be used as a recommended drug for advanced small cell lung cancer, which had a good effect on the treatment of brain metastasies; Etoposide or irinotecan could be combined with platinum as the first-line chemotherapy scheme, and if the first-line scheme was resistant to the drug, the second line scheme could be selected to be the second line scheme. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Can medical insurance reimburse biological immunity therapy for stomach cancer? How much is it once?
Regarding the medical insurance reimbursement of biological immune therapy for gastric cancer, different drugs were different. There was no problem with the reimbursement of Sindilitumab when it met the national requirements, that is, when it was diagnosed with gastric cancer and was the first-line treatment for advanced gastric cancer. The PDI score was not checked, but the information about the amount of each reimbursement was not found. If tirilibizumb was used, it would depend on the high expression of PD11 in advanced gastric cancer. At present, it was difficult to define this, and there were problems with reimbursement. As for the other PD1 drugs, they were not eligible for reimbursement for late-stage gastric cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the drugs that enhance breast cancer immunity?
In the treatment of breast cancer, some drugs can be used to enhance immunity. For example, non-specific active immune therapy drugs include bcg, thymosin, and ifon. In addition, immune checkpoint suppressors can fight breast cancer by activating the immune system. Common immune therapy drugs include pabolizumab, atezulizumab, etc. However, these drugs may cause adverse reactions such as cardiac toxicity and leukemia. Patients need to take them under the guidance of a doctor. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the best drugs for small cell immunity therapy?
What are the chemotherapy drugs for lung cancer?
There were mainly the following types of chemotherapy drugs for lung cancer: 1. ** Platinum-based combination drug **: - Cisplatine or chemotherapy is often used in combination with other chemotherapy drugs. For example, the combination of chemotherapy and gemcitobin was a common treatment. 2. ** Other commonly used drugs **: - Paclitaxel-bound taxol was commonly used in clinical practice. However, some patients would have allergic reactions, so a drug sensitivity test had to be performed before taking the drug. - Etoposide. - Gemcitobin was more effective, but it was not recommended for patients who were receiving synchronous chemotherapy and chemotherapy, as it might cause complications such as lung edema. - Vinorelbine. - Docethereal, which can be used in combination with ramoirubin for second-line treatment of patients with metastasized non-small cell lung cancer (including squamous-cell lung cancer). 3. ** Medicines for special circumstances **: - Necitumamoto was approved for use in combination with cisplatinum-based therapy and gemcitabine-based therapy in patients with metastasizing squamous-cell lung cancer. - Afantine can be used in patients with metastasized squamous-cell lung cancer who have progressed after platinum-based chemotherapy. The use of these drugs must be carried out under the guidance of a doctor, and the choice of drugs will depend in part on factors such as the patient's overall health and ability to tolerate side effects. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the drugs for treating lung cancer?
The treatment for lung cancer included: 1. * * chemotherapy drugs **: - For lung cancer, the commonly used chemotherapy drugs were chemotherapy, taxol, vincristine, gemcitobin, and so on. - For small-cell lung cancer, you can choose to use Etoposide, MTX, cyclosporine, and so on. 2. * * Target therapy drug **: - There are gefitini, erlotini, etc. targeting the egfr gene; suitable for patients with locally advanced or metastasized advanced non-small cell lung cancer with sensitive mutations in the egfr gene (e.g., gefitini is suitable for advanced non-small cell lung cancer that has failed platinum therapy in the past, erlotini is used for third-line treatment of locally advanced or metastasized non-small cell lung cancer that has failed two or more chemotherapy schemes, etc.). - Crizotini and others targeted the ROS1 gene. Patients with ALK fusion gene positive could choose alectinib, ceritini, or crizotini for treatment; patients with ROS1 fusion gene positive could choose crizotini for treatment; patients with C-met 14 jump mutation who could not tolerate chemotherapy could choose savortinib. For patients with a positive driver gene (such as a positive mutation in the egfr-gene), they could choose to be treated with an Epidermal Growth factor receptor Tyrosin Kinase Inhibition (egfr-TKi), including gefitini, erlotini, icotini, dacotini, afartini, or osimertinib. 3. * * Immune therapy drugs **: For example, Sindilitumab (PD-1 immune drug), PDL-1 immune suppressors, etc. In the treatment of lung cancer, immune therapy drugs can also be used in combination with chemotherapy (for example, immune therapy drugs have a synergy with chemotherapy from the beginning, and the chemotherapy drugs kill cancer cells and release the immune cells). For patients with lung cancer and pneumonias, they might also be given Dexamethason capsules, which could have anti-inflammatory and anti-allergic effects, improve the body's immunity, and promote metabolism and blood circulation. It should be noted that the treatment of lung cancer should strictly control the clinical indications and be carried out under the guidance of an oncologist. Molecular-targeted therapy needed to determine the gene mutation status and guide targeted therapy according to molecular typing. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
70-year-old advanced lung cancer can live for a few years with targeted drugs
For patients with late-stage lung cancer who took targeted drugs, the time from the start of treatment to the progression of the disease or the patient's death was 9.2 to 18.9 months. The general overall survival period was 21.6 to 36 months. There was also data that showed that the average survival time was about three years, but this was only a rough range. The specific situation needs to be determined based on the patient's physical condition (such as whether the patient has cardiovascular diseases, chronic rheumatism, liver diseases, and other basic diseases), the effect of targeted therapy, the patient's attitude and degree of cooperation with the treatment, as well as the support, care, and economic investment of the family members. There are individual differences. Some studies had shown that after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the mean survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the mean survival time was 6 months. In addition, with the deepening of targeted drug research, more efficient targeted drugs could effectively prolong the survival of patients with advanced lung cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>